A Perspective on the contribution of metabolites to drug-drug interaction potential: The need to consider both circulating levels and inhibition potency

Drug Metabolism and Disposition

Volumn 41, Issue 3, 2013, Pages 536-540

  Yu, Hongbin ^a   Tweedie, Donald ^a  

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMIODARONE; ATORVASTATIN; CYTOCHROME P450; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; DEETHYLAMIODARONE; DRUG METABOLITE; ERTHROHYDROBUPROPION; GEMFIBROZIL; GEMFIBROZIL GLUCURONIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PACLITAXEL; SERTRALINE; THEOPHYLLINE; THREOHYDROBUPROPION; UNCLASSIFIED DRUG; WARFARIN;

AREA UNDER THE CURVE; BINDING AFFINITY; COMPETITIVE INHIBITION; DECISION TREE; DISSOCIATION CONSTANT; DRUG INTERACTION; DRUG METABOLISM; ENZYME INHIBITION; HUMAN; HYDROPHOBICITY; IC 50; IN VITRO STUDY; LIPOPHILICITY; MAXIMUM PLASMA CONCENTRATION; PATIENT SAFETY; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW;

ANIMALS; AREA UNDER CURVE; BIOTRANSFORMATION; CYTOCHROME P-450 ENZYME SYSTEM; DECISION TREES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENZYME INHIBITORS; HUMANS; MODELS, BIOLOGICAL; MODELS, STATISTICAL; MOLECULAR STRUCTURE; PHARMACEUTICAL PREPARATIONS; RISK ASSESSMENT; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84874038558     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.048892     Document Type: Review

References (28)

1. Backes WL, Cawley G, Eyer CS, Means M, Causey KM, and Canady WJ (1993) Aromatic hydrocarbon binding to cytochrome P450 and other enzyme binding sites: are hydrophobic compounds drawn into the active site or pushed from the aqueous phase? Arch Biochem Biophys 304:27-37.
2. Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, and Ni L, et al.; Pharmaceutical Research and Manufacturers of America (PhRMA) Drug Metabolism/Clinical Pharmacology Technical Working Group; ; FDA Center for Drug Evaluation and Research (CDER) (2003) The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 31:815-832.
3. Brown LM and Ford-Hutchinson AW (1982) The destruction of cytochrome P-450 by alclofenac: possible involvement of an epoxide metabolite. Biochem Pharmacol 31:195-199.
4. Chainuvati S, Nafziger AN, Leeder JS, Gaedigk A, Kearns GL, Sellers E, Zhang Y, Kashuba ADM, Rowland E, and Bertino JS, Jr (2003) Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase- 2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail". Clin Pharmacol Ther 74:437-447.
5. Didziapetris R, Dapkunas J, Sazonovas A, and Japertas P (2010) Trainable structure-activity relationship model for virtual screening of CYP3A4 inhibition. J Comput Aided Mol Des 24: 891-906.
6. Hanna MH, Peat SJ, Woodham M, Knibb A, and Fung C (1990) Analgesic efficacy and CSF pharmacokinetics of intrathecal morphine-6-glucuronide: comparison with morphine. Br J Anaesth 64:547-550.
7. Isoherranen N, Hachad H, Yeung CK, and Levy RH (2009) Qualitative analysis of the role of metabolites in inhibitory drug-drug interactions: literature evaluation based on the metabolism and transport drug interaction database. Chem Res Toxicol 22:294-298.
8. Jacobsen W, Kuhn B, Soldner A, Kirchner G, Sewing KF, Kollman PA, Benet LZ, and Christians U (2000) Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. Drug Metab Dispos 28:1369-1378.
9. Jenkins SM, Zvyaga T, Johnson SR, Hurley J, Wagner A, Burrell R, Turley W, Leet JE, Philip T, and Rodrigues AD (2011) Studies to further investigate the inhibition of human liver microsomal CYP2C8 by the acyl-b-glucuronide of gemfibrozil. Drug Metab Dispos 39: 2421-2430.
10. Johnston JJ, Draper WM, and Stephens RD (1991) LC-MS compatible HPLC separation for xenobiotics and their phase I and phase II metabolites: simultaneous anion exchange and reversed-phase chromatography. J Chromatogr Sci 29:511-516.
11. Lewis DF, Lake BG, Ito Y, and Dickins M (2006) Lipophilicity relationships in inhibitors of CYP2C9 and CYP2C19 enzymes. J Enzyme Inhib Med Chem 21:385-389.
12. Manyike PT, Kharasch ED, Kalhorn TF, and Slattery JT (2000) Contribution of CYP2E1 and CYP3A to acetaminophen reactive metabolite formation. Clin Pharmacol Ther 67: 275-282.
13. Marchiset D, Bruno R, Djiane P, Cano JP, Benichou M, and Serradimigni A (1985) Amiodarone and desethylamiodarone elimination kinetics following withdrawal of long-term amiodarone maintenance therapy. Biopharm Drug Dispos 6:209-215.
14. Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston JB, and Tremaine LM (2006) The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J Pharmacol Exp Ther 316:336-348.
15. Obach RS, Walsky RL, Venkatakrishnan K, Houston JB, and Tremaine LM (2005) In vitro cytochrome P450 inhibition data and the prediction of drug-drug interactions: qualitative relationships, quantitative predictions, and the rank-order approach. Clin Pharmacol Ther 78: 582-592.
16. Ogilvie BW, Zhang D, Li W, Rodrigues AD, Gipson AE, Holsapple J, Toren P, and Parkinson A (2006) Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions. Drug Metab Dispos 34:191-197.
17. Orr STM, Ripp SL, Ballard TE, Henderson JL, Scott DO, Obach RS, Sun H, and Kalgutkar AS (2012) Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks. J Med Chem 55: 4896-4933.
18. Patel BN, Sharma N, Sanyal M, and Shrivastav PS (2009) Analysis of second-generation antidepressant drug, sertraline and its active metabolite, N-desmethyl sertraline in human plasma by a sensitive and selective liquid chromatography-tandem mass spectrometry method. J Chromatogr B Analyt Technol Biomed Life Sci 877:221-229.
19. Petsalo A, Turpeinen M, and Tolonen A (2007) Identification of bupropion urinary metabolites by liquid chromatography/mass spectrometry. Rapid Commun Mass Spectrom 21:2547-2554.
20. Reese MJ, Wurm RM, Muir KT, Generaux GT, St John-Williams L, and McConn DJ (2008) An in vitro mechanistic study to elucidate the desipramine/bupropion clinical drug-drug interaction. Drug Metab Dispos 36:1198-1201.
21. Roy K and Pratim Roy P (2009) Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques. Eur J Med Chem 44:2913-2922.
22. Rudorfer MV and Potter WZ (1997) The role of metabolites of antidepressants in the treatment of depression. CNS Drugs 7:273-312.
23. Satoh H, Martin BM, Schulick AH, Christ DD, Kenna JG, and Pohl LR (1989) Human antiendoplasmic reticulum antibodies in sera of patients with halothane-induced hepatitis are directed against a trifluoroacetylated carboxylesterase. Proc Natl Acad Sci USA 86:322-326.
24. Streetman DS, Bleakley JF, Kim JS, Nafziger AN, Leeder JS, Gaedigk A, Gotschall R, Kearns GL, and Bertino JS, Jr (2000) Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail". Clin Pharmacol Ther 68:375-383.
25. Tornio A, Niemi M, Neuvonen M, Laitila J, Kalliokoski A, Neuvonen PJ, and Backman JT (2008) The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism-based inhibition of CYP2C8 in vivo. Clin Pharmacol Ther 84:403-411.
26. U.S. FDA (2006) Guidance for industry drug interaction studies-study design, data analysis, and implications for dosing and labeling, Draft Guidance. Center for Drug Evaluation and Research, Silver Springs, MD
27. VandenBrink BM and Isoherranen N (2010) The role of metabolites in predicting drug-drug interactions: focus on irreversible cytochrome P450 inhibition. Curr Opin Drug Discov Devel 13:66-77.
28. Yeung CK, Fujioka Y, Hachad H, Levy RH, and Isoherranen N (2011) Are circulating metabolites important in drug-drug interactions?: Quantitative analysis of risk prediction and inhibitory potency. Clin Pharmacol Ther 89:105-113.